Sino Biopharmaceutical Limited (hereinafter referred to as “Sino Biopharmaceutical”) is the pharmaceutical sector of Thailand's Charoen Pokphand Group in China. It is a leading innovation and research and development (R&D)-driven pharmaceutical group in China, with business covering the entire industry chain of R&D, manufacturing, and commercialization of innovative drugs, biological products, and high-end generic drugs. It holds a dominant position in four major therapeutic areas: oncology, hepatology/cardiometabolic diseases, respiratory/autoimmune diseases, and surgery/analgesia.
The company was listed on the Hong Kong Stock Exchange in 2000, with the stock code 01177. It was included as a constituent stock of the MSCI China Index under the MSCI Global Standard Index in 2013, the Hang Seng Index in 2018, the Hang Seng China Enterprises Index in 2019, and both the HS Stock Connect Biotech 50 Index and the Hang Seng China (Hong Kong-listed) 25 Index in 2020. Driven by sustained and steady development and outstanding achievements, the Company has been ranked among the "Top 50 Global Pharmaceutical Companies" published by a leading U.S. authority for 7 consecutive years and has been named one of Forbes "Asia's Best Public Companies Top 50" for 3 consecutive years.
Guided by its vision "to be a leading global pharmaceutical company through delivering innovative therapies for patients", Sino Biopharmaceutical has established drug R&D and manufacturing bases centered in Beijing, Shanghai, Guangzhou, Nanjing, and Lianyungang. Its subsidiaries, Chia Tai Tianqing Pharmaceutical Group and Beijing Tide Pharmaceutical Co., Ltd., have both been ranked among the "Top 100 Chinese Pharmaceutical Industrial Enterprises" for many years. Its wholly-owned subsidiaries, Lanova Medicines and Hygieia, focus on original innovation through their independently developed differentiated technology platforms. The company has a global R&D team of over 2,900 professionals, with cutting-edge technology platforms covering bispecific antibodies, antibody-drug conjugates (ADC), proteolysis-targeting chimeras (PROTAC), small nucleic acids, and more. Through diverse paths including independent innovation, international cooperation, and overseas out-licensing, the Company gathers global innovation resources and continuously expands its international influence.
Adhering to the philosophy of "Science for a Healthier World", Sino Biopharmaceutical remains committed to addressing unmet clinical needs as its guiding principle. The Company is dedicated to bringing safer, more effective, and more accessible treatment options to patients worldwide, while sharing the fruits of industrial development with all partners for a win-win future.
